- Home
- ADTN vs OCS Comparison
ADTN vs OCS Comparison
Compare ADTN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTN
- OCS
- Stock Information
- Founded
- ADTN 1985
- OCS 2003
- Country
- ADTN United States
- OCS Switzerland
- Employees
- ADTN N/A
- OCS N/A
- Industry
- ADTN Telecommunications Equipment
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- ADTN Telecommunications
- OCS Health Care
- Exchange
- ADTN Nasdaq
- OCS Nasdaq
- Market Cap
- ADTN 616.5M
- OCS 689.8M
- IPO Year
- ADTN 1994
- OCS N/A
- Fundamental
- Price
- ADTN $8.03
- OCS $19.45
- Analyst Decision
- ADTN Strong Buy
- OCS Strong Buy
- Analyst Count
- ADTN 4
- OCS 4
- Target Price
- ADTN $12.00
- OCS $31.50
- AVG Volume (30 Days)
- ADTN 888.9K
- OCS 29.0K
- Earning Date
- ADTN 05-07-2025
- OCS 05-08-2025
- Dividend Yield
- ADTN N/A
- OCS N/A
- EPS Growth
- ADTN N/A
- OCS N/A
- EPS
- ADTN N/A
- OCS N/A
- Revenue
- ADTN $944,291,000.00
- OCS $847,333.00
- Revenue This Year
- ADTN $13.90
- OCS $53.79
- Revenue Next Year
- ADTN $9.13
- OCS $1,860.95
- P/E Ratio
- ADTN N/A
- OCS N/A
- Revenue Growth
- ADTN N/A
- OCS N/A
- 52 Week Low
- ADTN $4.62
- OCS $10.79
- 52 Week High
- ADTN $12.44
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- ADTN 49.80
- OCS 58.76
- Support Level
- ADTN $7.65
- OCS $17.33
- Resistance Level
- ADTN $8.24
- OCS $20.45
- Average True Range (ATR)
- ADTN 0.27
- OCS 0.80
- MACD
- ADTN 0.02
- OCS 0.19
- Stochastic Oscillator
- ADTN 37.62
- OCS 68.75
About ADTN ADTRAN Holdings Inc.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.